PPI-1019 Uses, Dosage, Side Effects and more

Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

Trade Name PPI-1019
Generic PPI-1019
Type
Formula C36H54N6O5
Weight Average: 650.865
Monoisotopic: 650.415568863
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in alzheimer's disease.

How PPI-1019 works

PPI-1019 (Apan) inhibits the aggregation of
beta-amyloid and its associated nerve cell toxicity. In addition, Apan reaches the brain in quantities that are sufficient to
block the aggregation of beta-amyloid molecules and alter the course of the disease.

Accumulation of beta-amyloid in the brain is often thought of as a defect in the ability to clear beta-amyloid from the brain through the cerebral spinal fluid (CSF). Both humans and transgenic mice with Alzheimer's disease plaques show increased levels of beta-amyloid in the brain and decreased levels in the CSF. Transgenic mice treated with Apan show significant increases in beta-amyloid levels in the CSF, indicating that Apan is able to mobilize beta-amyloid in the brain and may be facilitating its clearance.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share